"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...
Diffuse large B cell lymphoma (DLBCL) is a prevalent subtype of non-Hodgkins lymphoma and can occasionally present as a rare and aggressive testicular variant. This case presents a middle-aged male ...
In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
Arima Genomics announces a new study showing that the Aventa™ lymphoma test resolves diagnostic ambiguity and guides care in ...
—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...
Hosted on MSN
Recent Developments in Diffuse Large B-Cell Lymphoma
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma. Results ...
Jeremy S Abramson and colleagues reported that glofitamab plus gemcitabine and oxaliplatin (GemOx) significantly improved overall survival (OS) in transplant-ineligible patients with relapsed or ...
Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback